Chimeric Antigen Receptor T-cell Therapy in Hematologic Malignancies and Patient-reported Outcomes: A Scoping Review
暂无分享,去创建一个
E. Bruera | M. Vignetti | F. Baron | M. Luppi | J. Giesinger | U. Platzbecker | F. Efficace | L. Cannella | F. Sparano | Francesco Sparano
[1] A. Schoenthaler,et al. A framework for digital health equity , 2022, npj Digital Medicine.
[2] M. Kersten,et al. Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma. , 2022, Blood.
[3] C. Zimmermann,et al. Early integration of palliative care for patients with haematological malignancies , 2022, British journal of haematology.
[4] B. Given,et al. Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer: A Randomized Clinical Trial. , 2022, JAMA.
[5] H. Jim,et al. Longitudinal Collection of Patient-Reported Outcomes and Activity Data during CAR-T Therapy: Feasibility, Acceptability, and Data Visualization , 2022, Cancers.
[6] P. Hari,et al. Patient-reported outcomes and neurotoxicity markers in patients treated with bispecific LV20.19 CAR T cell therapy , 2022, Communications Medicine.
[7] S. Bhatia,et al. Assessment of Hospitalizations and Emergency Department Visits After Chimeric Antigen Receptor T-Cell Therapy Among Commercially Insured Patients. , 2022, JAMA oncology.
[8] H. Jim,et al. Change in patients' perceived cognition following chimeric antigen receptor T-cell therapy for lymphoma. , 2022, Transplantation and cellular therapy.
[9] A. Dispenzieri,et al. Longitudinal Patient Reported Outcomes with CAR-T Cell Therapy vs Autologous and Allogeneic Stem Cell Transplant , 2022, Transplantation and Cellular Therapy.
[10] E. Basch,et al. The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO Clinical Practice Guideline. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] C. Dinardo,et al. Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia , 2022, Blood Cancer Journal.
[12] E. Bruera,et al. Early Palliative Care in Acute Myeloid Leukemia , 2022, Cancers.
[13] Hamed Manoochehri,et al. Use of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: a review study , 2022, Cancer gene therapy.
[14] N. Munshi,et al. Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma , 2021, Blood advances.
[15] M. Kersten,et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial , 2021, Nature Medicine.
[16] G. Salles,et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. , 2021, The Lancet. Oncology.
[17] A. Laganà,et al. Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy , 2021, Nature Medicine.
[18] D. Regier,et al. Health-related quality of life data collected in chimeric antigen receptor T-cell (CAR-T) therapy clinical trials , 2021, Journal of Cancer Policy.
[19] D. Miklos,et al. Do PROs Tell the Whole Story? Differential Outcomes Based on Patient-Reported Outcomes (PROs) Versus Performance-Based Metrics (PBM) on Cognition for Patients Receiving Chimeric Antigen Receptor (CAR)-T Cell Therapy , 2021, Blood.
[20] D. Dingli,et al. Pilot Implementation of Remote Patient Monitoring Program for Outpatient Management of CAR-T Cell Therapy , 2021, Blood.
[21] D. Miklos,et al. Worsening Financial Toxicity Among Patients Receiving Chimeric Antigen Receptor t-Cell (CAR-T) Therapy: A Mixed Methods Longitudinal Study , 2021, Blood.
[22] C. Yap,et al. Trends in patient‐reported outcome use in early phase dose‐finding oncology trials – an analysis of ClinicalTrials.gov , 2021, Cancer medicine.
[23] C. Porta,et al. Cross-sectional study to develop and describe psychometric characteristics of a patient-reported instrument (PROFFIT) for measuring financial toxicity of cancer within a public healthcare system , 2021, BMJ Open.
[24] M. Kersten,et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. , 2021, The Lancet. Oncology.
[25] D. Miklos,et al. Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma , 2021, Blood advances.
[26] C. Cleeland,et al. Patient-reported symptom and functioning status during the first 12 months after CAR T-cell therapy for hematological malignancies. , 2021, Transplantation and cellular therapy.
[27] D. Hagin,et al. Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients – a matched control multicenter cohort study , 2021, Haematologica.
[28] S. Jagannath,et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study , 2021, The Lancet.
[29] R. Houot,et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study , 2021, The Lancet.
[30] S. Mohile,et al. Understanding Treatment Tolerability in Older Adults With Cancer. , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] D. Patrick,et al. Effect of lisocabtagene maraleucel on HRQoL and symptom severity in relapsed/refractory large B-cell lymphoma. , 2021, Blood advances.
[32] M. Vignetti,et al. The GIMEMA-ALLIANCE Digital Health Platform for Patients With Hematologic Malignancies in the COVID-19 Pandemic and Postpandemic Era: Protocol for a Multicenter, Prospective, Observational Study , 2020, JMIR research protocols.
[33] S. Cuzzubbo,et al. Evaluation of mid-term (6-12 months) neurotoxicity in B-cell lymphoma patients treated with CAR T-cells: a prospective cohort study. , 2021, Neuro-oncology.
[34] E. Mayo-Wilson,et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2021, BMJ.
[35] H. Jim,et al. Quality of life in caregivers of patients receiving chimeric antigen receptor T‐cell therapy , 2021, Psycho-oncology.
[36] B. Hill,et al. Late Effects after Chimeric Antigen Receptor T cell Therapy for Lymphoid Malignancies. , 2021, Transplantation and cellular therapy.
[37] H. Jim,et al. Acute patient‐reported outcomes in B‐cell malignancies treated with axicabtagene ciloleucel , 2021, Cancer medicine.
[38] H. Goldschmidt,et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. , 2021, The New England journal of medicine.
[39] L. Minasian,et al. Underreporting of symptomatic adverse events in phase I clinical trials. , 2021, Journal of the National Cancer Institute.
[40] X. Wang,et al. Patient-Reported Outcomes for Cancer Patients with Hematological Malignancies Undergoing Chimeric Antigen Receptor T Cell Therapy: A Systematic Review. , 2021, Transplantation and cellular therapy.
[41] Oreofe O. Odejide. Strategies for introducing palliative care in the management of relapsed or refractory aggressive lymphomas. , 2020, Hematology. American Society of Hematology. Education Program.
[42] É. Azoulay,et al. Description of neurotoxicity in a series of patients treated with CAR T-cell therapy , 2020, Scientific Reports.
[43] P. Hari,et al. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial , 2020, Nature Medicine.
[44] Michael L. Wang,et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study , 2020, The Lancet.
[45] Thomas J. Smith,et al. Using Patient-Reported Outcomes to Describe the Patient Experience on Phase I Clinical Trials , 2020, JNCI cancer spectrum.
[46] Bryon D Johnson,et al. Delayed neurotoxicity after axicabtagene ciloleucel therapy in relapsed refractory diffuse large B-cell lymphoma , 2020, Bone Marrow Transplantation.
[47] E. Basch,et al. Use of Patient-Reported Outcomes to Understand & Measure the Patient Experience of Novel Cell and Gene Therapies , 2020, Therapeutic Innovation & Regulatory Science.
[48] K. Norga,et al. EMA Review of Axicabtagene Ciloleucel (Yescarta) for the Treatment of Diffuse Large B-Cell Lymphoma. , 2020, The oncologist.
[49] Michael L. Wang,et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. , 2020, The New England journal of medicine.
[50] F. Efficace,et al. Importance of quality of life in early phase clinical trials: A case study of selinexor in multiple myeloma , 2020, British journal of haematology.
[51] G. Salles,et al. Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma. , 2020, Blood advances.
[52] M. Bar,et al. Late events after treatment with CD19-Targeted Chimeric Antigen Receptor Modified T-cells. , 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[53] K. Davis,et al. Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial. , 2019, The Lancet. Oncology.
[54] M. Bar,et al. Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor-T Cell Therapy. , 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[55] M. Dimopoulos,et al. Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. , 2019, The New England journal of medicine.
[56] S. Riva,et al. Assessing Financial Toxicity in Patients With Cancer: Moving Away From a One-Size-Fits-All Approach. , 2019, Journal of oncology practice.
[57] Matthew J. Frigault,et al. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. , 2019, Blood.
[58] S. Sidana,et al. Patient-Reported Outcomes with Chimeric Antigen Receptor T Cell Therapy: Challenges and Opportunities. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[59] I. Flinn,et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. , 2019, The Lancet. Oncology.
[60] S. Grupp,et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[61] A. Tricco,et al. Chapter 11: Scoping Reviews , 2019, JBI Manual for Evidence Synthesis.
[62] G. Salles,et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B‐Cell Lymphoma , 2019, The New England journal of medicine.
[63] C. Turtle,et al. Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies , 2018, CNS Drugs.
[64] J. McGowan,et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation , 2018, Annals of Internal Medicine.
[65] H. Dombret,et al. Health-related quality of life in adults with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab. , 2018, Blood.
[66] L. Deangelis,et al. Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia. , 2018, Cancer discovery.
[67] H. Kantarjian,et al. Patient‐reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia , 2018, Cancer.
[68] Omkar U. Kawalekar,et al. CAR T cell immunotherapy for human cancer , 2018, Science.
[69] K. Davis,et al. Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic Leukemia , 2018, The New England journal of medicine.
[70] P. Hwu,et al. Chimeric antigen receptor T-cell therapy — assessment and management of toxicities , 2018, Nature Reviews Clinical Oncology.
[71] L. Minasian,et al. Use of PRO Measures to Inform Tolerability in Oncology Trials: Implications for Clinical Review, IND Safety Reporting, and Clinical Site Inspections , 2017, Clinical Cancer Research.
[72] Stephen J. Schuster,et al. Chimeric Antigen Receptor T Cells in Refractory B‐Cell Lymphomas , 2017, The New England journal of medicine.
[73] R. Levy,et al. Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma , 2017, The New England journal of medicine.
[74] M. Wurfel,et al. Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells. , 2017, Cancer discovery.
[75] J. Cerhan,et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. , 2017, Blood.
[76] F. Lo‐Coco,et al. Patient-reported outcomes in hematology: is it time to focus more on them in clinical trials and hematology practice? , 2017, Blood.
[77] Katie Kingwell. CAR T therapies drive into new terrain , 2017, Nature Reviews Drug Discovery.
[78] N. Schmitz,et al. Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study , 2017, Bone Marrow Transplantation.
[79] M. Ratain,et al. Measuring financial toxicity as a clinically relevant patient‐reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST) , 2016, Cancer.
[80] C. Gridelli,et al. The association of financial difficulties with clinical outcomes in cancer patients: secondary analysis of 16 academic prospective clinical trials conducted in Italy. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[81] Deborah Schrag,et al. Association of Financial Strain With Symptom Burden and Quality of Life for Patients With Lung or Colorectal Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[82] P. Newcomb,et al. Financial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[83] S. Heimfeld,et al. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor–modified T cells , 2016, Science Translational Medicine.
[84] N. Schmitz,et al. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study , 2016, Bone Marrow Transplantation.
[85] Amy P Abernethy,et al. Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). , 2015, JAMA oncology.
[86] R. Schlenk,et al. Randomized phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: health-related quality-of-life outcomes. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[87] Pamela A Shaw,et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.
[88] Qing He,et al. Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia , 2014, Science Translational Medicine.
[89] E. Basch. Toward patient-centered drug development in oncology. , 2013, New England Journal of Medicine.
[90] G. Nahler. European Public Assessment Report (EPAR) , 2009 .
[91] Megan Sorenson,et al. Library , 1958 .